Rezolute, Inc. RZLT
3.96 USD -0.05 (-1.25%)
At closeNov 4, 2026, 4:01 PM EST
3.96 0.00 0.00%
After hours · Nov 4, 4:01 PM ET
3.95 Day range 4.34
1.07 52-week range 11.46
- YTD
- +67.80%
- 1 year
- -55.51%
News
defenseworld.net Rezolute (NASDAQ:RZLT) Share Price Breaks Above 200 Day Moving Average – Here’s What Happened Rezolute, Inc. (NASDAQ: RZLT - Get Free Report)'s share price crossed above its 200-day moving average during trading on Tuesday. The stock has a 200-day moving average of $3.89 and traded as high as…
globenewswire.com Rezolute to Participate in Upcoming Investor Conferences REDWOOD CITY, Calif., Nov. 02, 2026 (GLOBE NEWSWIRE) -- Rezolute, Inc. (Nasdaq: RZLT) (Rezolute or Company), a late-stage ultra-rare, metabolic disease company focused on treating refractory…
defenseworld.net Rezolute (NASDAQ:RZLT) Stock Price Crosses Below 200-Day Moving Average – What’s Next? Rezolute, Inc. (NASDAQ: RZLT - Get Free Report)'s stock price crossed below its two hundred day moving average during trading on Monday. The stock has a two hundred day moving average of $3.84 and…
benzinga.com Rezolute Completes Enrollment In Open-Label Phase 3 Study Of Ersodetug In Tumor HI; Topline Data Expected In Mid-December 2026 Rezolute, Inc. (NASDAQ:RZLT) (Rezolute or Company), a late-stage ultra-rare disease company focused on treating refractory hypoglycemia caused by any form of hyperinsulinism (HI), today announced…
globenewswire.com Rezolute Announces Completion of Enrollment in Phase 3 upLIFT Study of Ersodetug in Tumor Hyperinsulinism Topline results expected mid-December 2026 REDWOOD CITY, Calif., Oct. 14, 2026 (GLOBE NEWSWIRE) -- Rezolute, Inc. (Nasdaq: RZLT) (Rezolute or Company), a late-stage ultra-rare disease company focused…
defenseworld.net Rezolute, Inc. (NASDAQ:RZLT) Stock Now Rated “Moderate Buy” by Sell-Side Analysts Rezolute, Inc. (NASDAQ: RZLT - Get Free Report) has been assigned an average recommendation of "Moderate Buy" from the fourteen analysts that are currently covering the company, Marketbeat.com…
benzinga.com This NetApp Analyst Turns Bullish; Here Are Top 5 Upgrades For Wednesday Analysts upgraded NetApp, Humana, Corteva, Afya, with price-target changes for four stocks.
benzinga.com Lake Street Maintains Buy on Rezolute, Raises Price Target to $12 Lake Street analyst Daniel Brims maintains Rezolute (NASDAQ:RZLT) with a Buy and raises the price target from $9 to $12.
benzinga.com Citizens Maintains Market Outperform on Rezolute, Raises Price Target to $15 Citizens analyst Jason N. Butler maintains Rezolute (NASDAQ:RZLT) with a Market Outperform and raises the price target from $11 to $15.
benzinga.com This Boyd Gaming Analyst Turns Bullish; Here Are Top 5 Upgrades For Tuesday Analysts upgraded Boyd Gaming, NeoGenomics, PENN Entertainment, XP and Rezolute, raising targets for several names.
benzinga.com FDA Recommends Meeting for Rezolute Drug for Rare Blood Sugar Disorder Despite Missed Endpoints Rezolute (NASDAQ: RZLT) shares surged after the FDA recommended a pre-BLA meeting for its congenital hyperinsulinism drug, ersodetug.
defenseworld.net Rezolute (NASDAQ:RZLT) Stock Sees Unusually High Call Option Buying Rezolute, Inc. (NASDAQ: RZLT - Get Free Report) was the recipient of some unusual options trading activity on Monday. Traders acquired 4,099 call options on the company. This is an increase of 618%…
benzinga.com Rezolute Gets FDA Recommendation For Pre-BLA Meeting Ahead Of Ersodetug BLA Submission For Congenital Hyperinsulinism Treatment. The Agency reiterated its commitment to addressing the unmet need for treatment of congenital and tumor-related hyperinsulinism and to serving these patient communities On track to report topline…
globenewswire.com Rezolute Announces FDA Recommendation to Hold a Pre-BLA Meeting as a Precursor to Submitting a Biologics License Application (BLA) for Congenital Hyperinsulinism The Agency reiterated its commitment to addressing the unmet need for treatment of congenital and tumor-related hyperinsulinism and to serving these patient communities
benzinga.com Why Vicor Shares Are Trading Higher By Around 12%; Here Are 20 Stocks Moving Premarket Vicor shares surged 12% after raising Q3 growth guidance above 30%; Roze AI led gainers, while Corteva plunged 57% premarket.
benzinga.com Lake Street Initiates Coverage On Rezolute with Buy Rating, Announces Price Target of $9 Lake Street analyst Daniel Brims initiates coverage on Rezolute (NASDAQ:RZLT) with a Buy rating and announces Price Target of $9.
benzinga.com This Staar Surgical Analyst Turns Bullish; Here Are Top 5 Upgrades For Tuesday Analysts upgraded STAA, NFLX, SFIX, with ratings moving toward Buy or Neutral and mixed price-target changes.
benzinga.com Craig-Hallum Upgrades Rezolute to Buy, Raises Price Target to $7 Craig-Hallum analyst Albert Lowe upgrades Rezolute (NASDAQ:RZLT) from Hold to Buy and raises the price target from $4 to $7.
benzinga.com 5 Stock Picks Last Week From Wall Street's Most Accurate Analysts U.S. stocks rose as oil fell on Strait of Hormuz hopes; Benzinga highlights top analysts’ picks: OKTA, AKAM and TELA.- benzinga.com HC Wainwright & Co. Maintains Buy on Rezolute, Raises Price Target to $10 HC Wainwright & Co. analyst Douglas Tsao maintains Rezolute (NASDAQ:RZLT) with a Buy and raises the price target from $5 to $10.
- benzinga.com Rezolute Q4 EPS $(0.20) Misses $(0.15) Estimate Rezolute (NASDAQ:RZLT) reported quarterly losses of $(0.20) per share which missed the analyst consensus estimate of $(0.15) by 33.33 percent. This is a 23.08 percent increase over losses of $(0.26)…
globenewswire.com Rezolute Reports Fourth Quarter and Full Year Fiscal 2026 Financial Results and Provides Business Update REDWOOD CITY, Calif., Sept. 24, 2026 (GLOBE NEWSWIRE) -- Rezolute, Inc. (Nasdaq: RZLT) (“Rezolute” or the “Company”), a late-stage ultra-rare rare disease company focused on treating refractory…
defenseworld.net Rezolute, Inc. (NASDAQ:RZLT) Receives $9.38 Average Price Target from Analysts Shares of Rezolute, Inc. (NASDAQ: RZLT - Get Free Report) have earned a consensus recommendation of "Moderate Buy" from the twelve analysts that are presently covering the firm, MarketBeat reports.…- benzinga.com Rezolute Said FDA Is Still Reviewing Ersodetug Submission In Congenital Hyperinsulinism; The Company Continues To Await Feedback And Reserves The Ability To Request Formal Meeting Under Regulatory Timeline Data from the Phase 3 sunRIZE study remains under review by FDA The OLE Phase of the study is ongoing, with a high participation rate and several indicators of improved glycemic control, including a…
globenewswire.com Rezolute Provides Update on FDA Review of its Phase 3 sunRIZE Study Results in Congenital Hyperinsulinism Data from the Phase 3 sunRIZE study remains under review by FDA The OLE Phase of the study is ongoing, with a high participation rate and several indicators of improved glycemic control, including a…
globenewswire.com Rezolute to Participate in Upcoming Investor Conferences REDWOOD CITY, Calif., Sept. 02, 2026 (GLOBE NEWSWIRE) -- Rezolute, Inc. (Nasdaq: RZLT) (“Rezolute” or the “Company”), a late-stage ultra-rare disease company focused on treating refractory…
defenseworld.net Rezolute, Inc. $RZLT Shares Sold by Bank of America Corp DE Bank of America Corp DE reduced its stake in Rezolute, Inc. (NASDAQ: RZLT) by 31.3% during the undefined quarter, according to its most recent Form 13F filing with the Securities and Exchange…
benzinga.com MARA Holdings, Coinbase Global, Ternium And Other Big Stocks Moving Higher On Friday Dow Jones index gained around 350 points on Friday. MARA Holdings Inc (NASDAQ: MARA) rose sharply, while Bitcoin (CRYPTO: BTC) also traded higher. Other stocks recording gains include Evolution…
globenewswire.com Rezolute to Participate in the BTIG Virtual Biotechnology Conference REDWOOD CITY, Calif., July 21, 2026 (GLOBE NEWSWIRE) -- Rezolute, Inc. (Nasdaq: RZLT) (“Rezolute” or the “Company”), a late-stage ultra-rare disease company focused on treating refractory…
benzinga.com Rezolute Highlights ENDO Data On Congenital HI Outcomes And Tumor HI Case Series Supporting Ersodetug Program Presentations included analyses of natural history and adverse outcomes in congenital hyperinsulinism (HI), as well as previously reported results from the Company's Phase 3 sunRIZE study in…
globenewswire.com Rezolute Highlights Results Presented from Natural History Outcomes Studies and its Ersodetug Clinical Program in Hyperinsulinism at Annual Meeting of the Endocrine Society Presentations included analyses of natural history and adverse outcomes in congenital hyperinsulinism (HI), as well as previously reported results from the Company's Phase 3 sunRIZE study in…
benzinga.com Guggenheim Maintains Buy on Rezolute, Raises Price Target to $11 Guggenheim analyst Debjit Chattopadhyay maintains Rezolute (NASDAQ:RZLT) with a Buy and raises the price target from $6 to $11.
zacks.com RZLT Stock on the Move: What Sparks the 38% Jump in the Past Week? Rezolute rises 38% in a week after interim upLIFT data shows most tumor HI patients cut or eliminate IV glucose support.- benzinga.com Rezolute To Present Four Presentations At Upcoming Annual Meeting Of Endocrine Society Rezolute, Inc. (NASDAQ:RZLT) ("Rezolute" or the "Company"), a late-stage ultra-rare disease company focused on treating refractory hypoglycemia caused by a congenital or any acquired form of…
globenewswire.com Rezolute Announces Four Presentations at the Upcoming Annual Meeting of the Endocrine Society REDWOOD CITY, Calif., June 04, 2026 (GLOBE NEWSWIRE) -- Rezolute, Inc. (Nasdaq: RZLT) (“Rezolute” or the “Company”), a late-stage ultra-rare disease company focused on treating refractory…- benzinga.com Maxim Group Maintains Buy on Rezolute, Raises Price Target to $14 Maxim Group analyst Jason McCarthy maintains Rezolute (NASDAQ:RZLT) with a Buy and raises the price target from $10 to $14.
benzinga.com Navitas Semiconductor, Abivax, MiniMed And Other Big Stocks Moving Higher On Wednesday Dow falls 296 points. Navitas Semi rises on partnership with Nvidia. Other gainers: ABVX, MMED, KELYB, NN, BVC, MX, ECX, DRTS, RZLT, SYRE, TGTX.
benzinga.com Citizens Upgrades Rezolute to Market Outperform, Announces $11 Price Target Citizens analyst Jason N. Butler upgrades Rezolute (NASDAQ:RZLT) from Market Perform to Market Outperform and announces $11 price target.- benzinga.com Wedbush Maintains Outperform on Rezolute, Raises Price Target to $6 Wedbush analyst Yun Zhong maintains Rezolute (NASDAQ:RZLT) with a Outperform and raises the price target from $5 to $6.
benzinga.com Marvell Technology Soars on NVIDIA CEO's Endorsement, Joins Relmada Therapeutics and Other Big Stocks Moving Higher in Wednesday's Pre-Market Session U.S. stock futures surged on Wed. as Nasdaq futures rose over 7%, driven by AI. Marvell's stock jumped 11.73%.
benzinga.com Rezolute Highlights Strong Early Response Trends In Rare Hypoglycemia Disease Study Rezolute, Inc. (NASDAQ:RZLT) reported an interim update from its ongoing Phase 3 upLIFT study evaluating ersodetug in patients with tumor hyperinsulinism (HI), saying six of the eight participants…
benzinga.com Rezolute Highlights Strong Early Response Trends In Rare Hypoglycemia Disease Study Rezolute says 6 of 8 patients met the primary endpoint in its Phase 3 upLIFT study of ersodetug for tumor hyperinsulinism.- benzinga.com HC Wainwright & Co. Reiterates Buy on Rezolute, Maintains $5 Price Target HC Wainwright & Co. analyst Douglas Tsao reiterates Rezolute (NASDAQ:RZLT) with a Buy and maintains $5 price target.
- benzinga.com Rezolute Reports Mid-Study Results for Rare Hypoglycemia Treatment Rezolute, Inc. (NASDAQ:RZLT) ("Rezolute" or the "Company"), a late-stage ultra-rare disease company focused on treating refractory hypoglycemia caused by a congenital or any acquired form of…
globenewswire.com Rezolute Announces Positive Interim Data for its Phase 3 upLIFT Study of Ersodetug in Tumor Hyperinsulinism Study now 50% enrolled 6 of 8 participants have already met the responder criterion for the study's primary endpoint Topline results for the fully enrolled open-label study are expected in the second…- benzinga.com Maxim Group Maintains Buy on Rezolute, Raises Price Target to $10 Maxim Group analyst Jason McCarthy maintains Rezolute (NASDAQ:RZLT) with a Buy and raises the price target from $4 to $10.
- benzinga.com Rezolute Q3 EPS $(0.16), Inline Rezolute (NASDAQ:RZLT) reported quarterly losses of $(0.16) per share which met the analyst consensus estimate. This is a 40.74 percent increase over losses of $(0.27) per share from the same period…
globenewswire.com Rezolute Reports Third Quarter Fiscal 2026 Financial Results and Provides Business Update REDWOOD CITY, Calif., May 12, 2026 (GLOBE NEWSWIRE) -- Rezolute, Inc. (Nasdaq: RZLT) (“Rezolute” or the “Company”), a late-stage rare disease company focused on treating hypoglycemia caused by all…
globenewswire.com Rezolute to Participate in Upcoming Investor Conferences REDWOOD CITY, Calif., May 11, 2026 (GLOBE NEWSWIRE) -- Rezolute, Inc. (Nasdaq: RZLT) (“Rezolute” or the “Company”), a late-stage rare disease company focused on treating hypoglycemia caused by all…- benzinga.com Rezolute Presents Expanded Phase 3 Data Showing Ersodetug Delivers Significant; Sees Consistent Glycemic Improvements And Sustained Benefits In Congenital Hyperinsulinism Patients Includes results from additional continuous glucose monitoring (CGM)-based outcomes which demonstrate significant and consistent improvements in glycemic control in ersodetug treatment arms compared…